Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prenetics Global Limited Class A Ordinary Share (PRE)

Prenetics Global Limited Class A Ordinary Share (PRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Prenetics Global Limited Class A Ordinary Share Unit 703-706 K11 Atelier King's Road 728 King's Road Quarry Bay K3 00000 HKG

www.prenetics.com Employees: 285

Sector:

Medical

Description:

Prenetics, a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Their prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, their joint venture with renowned scientist Prof. Dennis Lo, underscores their unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Lastly, ACT Genomics, their treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics' units synergistically enhances their global impact on health, truly embodying their commitment to 'enhancing life through science'.

Key Statistics

Overview:

Market Capitalization, $K 286,917
Enterprise Value, $K 234,667
Shares Outstanding, K 16,828
Float, K 15,515
% Float 92.20%
Short Interest, K 110
Short Float 0.65%
Days to Cover 1.00
Short Volume Ratio 0.45
% of Insider Shareholders 7.80%
% of Institutional Shareholders 25.01%

Financials:

Annual Sales, $ 30,620 K
Annual Net Income, $ -46,300 K
Last Quarter Sales, $ 23,560 K
Last Quarter Net Income, $ -7,410 K
EBIT, $ -43,430 K
EBITDA, $ -37,500 K

Growth:

1-Year Return 218.69%
3-Year Return 12.54%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.41 on 11/10/25
Next Earnings Date 06/11/26
Earnings Per Share ttm -2.03
EPS Growth vs. Prev Qtr 34.15%
EPS Growth vs. Prev Year -10.78%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Next Ex-Dividends Date 02/17/16
Dividend Payable Date 12/19/14
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 11/14/23

PRE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -19.07%
Return-on-Assets % -15.38%
Profit Margin % -151.21%
Debt/Equity 0.00
Price/Sales 3.52
Price/Cash Flow N/A
Price/Book 1.86
Book Value/Share 9.58
Interest Coverage -0.10
60-Month Beta 0.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar